Hepatitis C News

HCV screening varied among practices that served disadvantaged populations in the United States despite the implementation of an intervention to improve adherence to U.S. Preventive Services Task Force guidelines, according to a study published in the Annals of Internal Medicine.

Patients with liver disease, especially those with advanced liver disease, may face comorbid renal-related complications including impaired renal function and hepatorenal syndrome. Liver disease and kidney care have also been tied lately between use of hepatitis C-infected kidneys in nonviremic patients.

This year’s The Liver Meeting provided many exciting updates for viral hepatitis care ranging from steps toward eliminating hepatitis C to improving hepatitis B treatment options through data on hepatitis D.

Trio Health presented results from four studies at The Liver Meeting 2019 that showed novel outcomes in patients treated for hepatitis B with Vemlidy or hepatitis C with Vosevi.

The FDA approved changes to the product labels for direct-acting antivirals Harvoni, Epclusa, and Vosevi to include new efficacy and safety data for adults with hepatitis C and severe renal impairment, including those who require dialysis.

BOSTON — The Hepatitis C Leaders in Primary Care program, or HELP-C, engaged primary care physicians to successfully screen and treat veterans with hepatitis C through comanagement with a specialist liver team, according to a study presented at The Liver Meeting 2019.

BOSTON — New incidences of hepatitis C virus infection among men who have sex with men, or MSM, who are actively using pre-exposure prophylaxis for HIV prevention appeared to be less common than previously shown, according to data presented at The Liver Meeting 2019.

BOSTON — In this exclusive video from The Liver Meeting 2019, Robert S. Brown Jr., MD, MPH, of Weill Cornell Medical College, discusses the results of the EXPEDITION-8 trial, which demonstrated that treatment with Mavyret over 8 weeks was effective and had a favorable safety profile in patients with treatment-naive chronic hepatitis C virus genotypes 1-6 and compensated cirrhosis.

BOSTON — Hepatitis C infection was prevented or rapidly cured in transplant recipients who received organs from donors infected with the virus following combined treatment with ezetimibe and direct-acting antiviral therapy, according to study results presented at The Liver Meeting 2019.

Albumin levels and liver stiffness measurements taken during direct-acting antiviral therapy follow-up can stratify liver cancer risk among patients with hepatitis C and compensated advanced chronic liver disease, according to study results.